
COMMISSION REGULATION (EU) 2016/1179 of 19 July 2016 amending, for the purposes of its adaptation to technical and scientific progress, Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures (Text with EEA relevance) 

THE EUROPEAN COMMISSION,
Having regard to the Treaty on the Functioning of the European Union,
Having regard to Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006, and in particular Article 37(5) thereof,
Whereas:

(1) Part 3 of Annex VI to Regulation (EC) No 1272/2008 contains two lists of harmonised classification and labelling of hazardous substances. Table 3.1 lists the harmonised classification and labelling of hazardous substances based on the criteria set out in Parts 2 to 5 of Annex I to Regulation (EC) No 1272/2008. Table 3.2 lists the harmonised classification and labelling of hazardous substances based on the criteria set out in Annex VI to Council Directive 67/548/EEC.

(2) Since Directive 67/548/EEC has been repealed with effect from 1 June 2015, Table 3.2 in Part 3 of Annex VI should be deleted. However, in order to ease the transition to full applicability of Regulation (EC) No 1272/2008, that deletion should not take effect until 1 June 2017.

(3) Proposals for new, updated or deleted harmonised classification and labelling of certain substances have been submitted to the European Chemicals Agency (ECHA) pursuant to Article 37 of Regulation (EC) No 1272/2008. Based on the opinions on those proposals issued by the Committee for Risk Assessment of ECHA (RAC), as well as on the comments received from the parties concerned, it is appropriate to introduce, update or delete harmonised classification and labelling of certain substances.

(4) With regard to the substance lead, RAC proposes in its scientific opinion of 5 December 2013 to classify it as toxic for reproduction category 1A. However, in view of the lack of certainty regarding the bioavailability of lead in the massive form, a distinction needs to be made between the massive form (particle size more than or equal to 1 mm) and the powder form (particle size of less than 1 mm). It is therefore appropriate to introduce a specific concentration limit (SCL) of ≥ 0,03 % for the powder form and a generic concentration limit (GCL) of ≥ 0,3 % for the massive form.

(5) With regard to the copper substances, the environmental classification recommended in the RAC opinions of 4 December 2014 should be included in Annex VI to Regulation (EC) No 1272/2008 since sufficient scientific evidence is available justifying this new classification. However, the proposed M-factors for long-term aquatic hazard should not be included since they require further assessment by RAC in view of scientific data on aquatic toxicity presented by industry after the RAC opinion was forwarded to the Commission.

(6) Regulation (EC) No 1272/2008 should be amended accordingly.

(7) Compliance with the new harmonised classifications should not be required immediately, as a certain period of time will be necessary to allow suppliers to adapt the labelling and packaging of substances and mixtures to the new classifications and to sell existing stocks. This period of time will also be necessary to allow suppliers to adapt to and to comply with other legislative obligations resulting from the new harmonised classifications for substances such as those provided for in Article 22(f) or Article 23 of Regulation (EC) No 1907/2006 of the European Parliament and of the Council, those provided for in Article 50 of Regulation (EU) No 528/2012 of the European Parliament and of the Council or those in Article 44 of Regulation (EC) No 1107/2009 of the European Parliament and of the Council.

(8) In line with the transitional provisions of Regulation (EC) No 1272/2008 which allow the application of the new provisions at an earlier stage on a voluntary basis, suppliers should have the possibility of applying the new harmonised classifications and of adapting the labelling and packaging accordingly on a voluntary basis before the deadline for compliance.

(9) The measures provided for in this Regulation are in accordance with the opinion of the Committee established by Article 133 of Regulation (EC) No 1907/2006,
HAS ADOPTED THIS REGULATION:

Article 1 
Regulation (EC) No 1272/2008 is amended as follows:

((1)) Annex VI is amended in accordance with the Annex to this Regulation;
((2)) in Annex VI, Table 3.2 is deleted.
Article 2 

1. This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.
2. This Regulation shall apply from 1 March 2018.Article 1(2) shall apply from 1 June 2017.
3. By way of derogation from paragraph 2, substances and mixtures may, before 1 March 2018, be classified, labelled and packaged in accordance with Regulation (EC) No 1272/2008 as amended by this Regulation.
This Regulation shall be binding in its entirety and directly applicable in all Member States.Done at Brussels, 19 July 2016.
For the Commission
The President
Jean-Claude JUNCKER
ANNEX

Table 3.1 of Part 3 of Annex VI to Regulation (EC) No 1272/2008 is amended as follows:

((a)) the entries corresponding to index numbers 607-331-00-5 and 609-066-00-0 are deleted;
((b)) the entries corresponding to index numbers, 006-035-00-8, 029-002-00-X, 602-020-00-0, 602-033-00-1, 603-055-00-4, 604-030-00-0, 604-092-00-9, 605-013-00-0, 605-022-00-X, 606-014-00-9, 606-021-00-7, 607-056-00-0, 607-059-00-7, 607-157-00-X, 607-172-00-1, 607-375-00-5, 607-623-00-2, 613-166-00-X, 613-121-00-4, 616-011-00-4, 616-037-00-6 and 616-207-00-X are replaced by the following entries respectively:

Index No International Chemical Identification EC No CAS No Classification Labelling Specific Conc. Limits, M-factors Notes
Hazard Class and Category Code(s) Hazard statement Code(s) Pictogram, Signal Word Code(s) Hazard statement Code(s) Suppl. Hazard statement Code(s)
‘006-035-00-8 pirimicarb (ISO); 2-(dimethylamino)-5,6-dimethylpyrimidin-4-yl dimethylcarbamate 245-430-1 23103-98-2 Carc. 2Acute Tox. 3Acute Tox. 3Skin Sens. 1Aquatic Acute 1 Aquatic Chronic 1 H351H331H301H317H400H410 GHS08GHS06GHS09Dgr H351H331H301H317H410  M = 10M = 100’ 
‘029-002-00-X dicopper oxide;copper (I) oxide 215-270-7 1317-39-1 Acute Tox. 4Acute Tox. 4Eye Dam. 1Aquatic Acute 1Aquatic Chronic 1 H332H302H318H400H410 GHS07GHS05GHS09Dgr H332H302H318H410  M = 100’ 
‘602-020-00-0 1,2-dichloropropane;propylene dichloride 201-152-2 78-87-5 Flam. Liq. 2Carc. 1BAcute Tox. 4*Acute Tox. 4* H225H350H332H302 GHS02GHS08GHS07Dgr H225H350H332H302’   
‘602-033-00-1 chlorobenzene 203-628-5 108-90-7 Flam. Liq. 3Acute Tox. 4Skin Irrit. 2Aquatic Chronic 2 H226H332H315H411 GHS02GHS07GHS09Wng H226H332H315H411’   
‘603-055-00-4 propylene oxide;1,2-epoxypropane; methyloxirane 200-879-2 75-56-9 Flam. Liq. 1Carc. 1BMuta. 1BAcute Tox. 3Acute Tox. 3Acute Tox. 4STOT SE 3Eye Irrit. 2 H224H350H340H331H311H302H335H319 GHS02GHS08GHS06Dgr H224H350H340H331H311H302H335H319’   
‘604-030-00-0 bisphenol A;4,4′-isopropylidenediphenol 201-245-8 80-05-7 Repr. 1BSTOT SE 3Eye Dam. 1Skin Sens. 1 H360FH335H318H317 GHS08GHS05 GHS07Dgr H360FH335H318H317’   
‘604-092-00-9 phenol, dodecyl-, branched; [1]phenol, 2-dodecyl-, branched; [2]phenol, 3-dodecyl-, branched; [3]phenol, 4-dodecyl-, branched; [4]phenol, (tetrapropenyl) derivatives [5] 310-154-3 [1][2][3][4][5] 121158-58-5 [1][2][3]210555-94-5 [4]74499-35-7 [5] Repr. 1BSkin Corr. 1CEye Dam. 1Aquatic Acute 1 Aquatic Chronic 1 H360FH314H318H400H410 GHS08GHS05GHS09Dgr H360FH314H410  M = 10M = 10’ 
‘605-013-00-0 chloralose (INN);(R)-1,2-O-(2,2,2-trichloroethylidene)-α-D-glucofuranose; glucochloralose; anhydroglucochloral 240-016-7 15879-93-3 Acute Tox. 4*Acute Tox. 3STOT SE 3Aquatic Acute 1Aquatic Chronic 1 H332H301H336H400H410 GHS06GHS09Dgr H332H301H336H410  M = 10M = 10 C’
‘605-022-00-X glutaral; glutaraldehyde;1,5-pentanedial 203-856-5 111-30-8 Acute Tox. 2Acute Tox. 3STOT SE 3Skin Corr. 1BResp. Sens. 1Skin Sens. 1AAquatic Acute 1Aquatic Chronic 2 H330H301H335H314H334H317H400H411 GHS06GHS05GHS08GHS09Dgr H330H301H335H314H334H317H410 EUH071 STOT SE 3; H335: 0,5 % ≤ C < 5 %M = 1’ 
‘606-014-00-9 chlorophacinone (ISO);2-[(4-chlorophenyl)(phenyl)acetyl]-1H-indene-1,3(2H)-dione 223-003-0 3691-35-8 Repr. 1BAcute Tox. 1Acute Tox. 1Acute Tox. 1STOT RE 1Aquatic Acute 1Aquatic Chronic 1 H360DH330H310H300H372 (blood)H400H410 GHS08GHS06GHS09Dgr H360DH330H310H300H372 (blood)H410  Repr. 1B; H360D:C ≥ 0,003 %STOT RE 1; H372 (blood): C ≥ 0,1 %STOT RE 2; H373 (blood):0,01 % ≤ C < 0,1 %M = 1M = 1’ 
‘606-021-00-7 N-methyl-2-pyrrolidone; 1-methyl-2-pyrrolidone 212-828-1 872-50-4 Repr. 1BSTOT SE 3Skin Irrit. 2Eye Irrit. 2 H360D***H335H315H319 GHS08GHS07Dgr H360D***H335H315H319  STOT SE 3; H335: C ≥ 10 %’ 
‘607-056-00-0 warfarin (ISO);4-hydroxy-3-(3-oxo-1-phenylbutyl)-2H-chromen-2-one; [1](S)-4-hydroxy-3-(3-oxo-1-phenylbutyl)-2-benzopyrone; [2](R)-4-hydroxy-3-(3-oxo-1-phenylbutyl)-2-benzopyrone [3] 201-377-6[1]226-907-3[2]226-908-9[3] 81-81-2 [1]5543-57-7[2]5543-58-8[3] Repr. 1AAcute Tox. 1Acute Tox. 1Acute Tox. 2STOT RE 1Aquatic Chronic 2 H360DH330H310H300H372 (blood)H411 GHS08GHS06GHS09Dgr H360DH330H310H300H372 (blood)H411  Repr. 1A; H360D:C ≥ 0,003 %STOT RE 1; H372 (blood): C ≥ 0,5 %STOT RE 2; H373 (blood): 0,05 % ≤ C < 0,5 %’ 
‘607-059-00-7 coumatetralyl (ISO); 4-hydroxy-3-(1,2,3,4-tetrahydro-1-naphthyl)coumarin 227-424-0 5836-29-3 Repr. 1BAcute Tox. 2Acute Tox. 3Acute Tox. 2STOT RE 1Aquatic Chronic 1 H360DH330H311H300H372 (blood)H410 GHS08GHS06GHS09Dgr H360DH330H311H300H372 (blood)H410  Repr. 1B; H360D: C ≥ 0,003 %STOT RE 1; H372 (blood): C ≥ 1,0 %STOT RE 2; H373 (blood) 0,1 % ≤ C < 1,0 %M = 10’ 
‘607-157-00-X difenacoum (ISO); 3-(3-biphenyl-4-yl-1,2,3,4-tetrahydro-1-naphthyl)-4-hydroxycoumarin 259-978-4 56073-07-5 Repr. 1BAcute Tox. 1Acute Tox. 1Acute Tox. 1STOT RE 1Aquatic Acute 1Aquatic Chronic 1 H360DH330H310H300H372 (blood)H400H410 GHS08GHS06GHS09Dgr H360DH330H310H300H372 (blood)H410  Repr. 1B; H360D:C ≥ 0,003 %STOT RE 1; H372 (blood): C ≥ 0,02 % STOT RE 2; H373 (blood):0,002 % ≤ C < 0,02 %M = 10M = 10’ 
‘607-172-00-1 brodifacoum (ISO);4-hydroxy-3-(3-(4′-bromo-4-biphenylyl)-1,2,3,4-tetrahydro-1-naphthyl)coumarin 259-980-5 56073-10-0 Repr. 1AAcute Tox. 1Acute Tox. 1Acute Tox. 1STOT RE 1Aquatic Acute 1Aquatic Chronic 1 H360DH330H310H300H372 (blood)H400H410 GHS08GHS06GHS09Dgr H360DH330H310H300H372 (blood)H410  Repr. 1A; H360D:C ≥ 0,003 %STOT RE 1; H372 (blood): C ≥ 0,02 % STOT RE 2; H373 (blood):0,002 % ≤ C < 0,02 %M = 10M = 10’ 
‘607-375-00-5 flocoumafen (ISO); reaction mass of: cis-4-hydroxy-3-(1,2,3,4-tetrahydro-3-(4-(4-trifluoromethylbenzyloxy)phenyl)-1-naphthyl)coumarin and trans-4-hydroxy-3-(1,2,3,4-tetrahydro-3-(4-(4-trifluoromethylbenzyloxy)phenyl)-1-naphthyl)coumarin 421-960-0 90035-08-8 Repr. 1BAcute Tox. 1Acute Tox. 1Acute Tox. 1STOT RE 1Aquatic Acute 1Aquatic Chronic 1 H360DH330H310H300H372 (blood)H400H410 GHS08GHS06GHS09Dgr H360DH330H310H300H372 (blood)H410  Repr. 1B; H360D:C ≥ 0,003 %STOT RE 1; H372 (blood): C ≥ 0,05 %STOT RE 2; H373 (blood):0,005 % ≤ C < 0,05 %M = 10M = 10’ 
‘607-623-00-2 diisobutyl phthalate 201-553-2 84-69-5 Repr. 1B H360Df GHS08Dgr H360Df’   
‘613-166-00-X flumioxazin (ISO);2-[7-fluoro-3-oxo-4-(prop-2-yn-1-yl)-3,4-dihydro-2H-1,4-benzoxazin-6-yl]-4,5,6,7-tetrahydro-1H-isoindole-1,3(2H)-dione — 103361-09-7 Repr. 1BAquatic Acute 1Aquatic Chronic 1 H360DH400H410 GHS08GHS09Dgr H360DH410  M = 1 000M = 1 000’ 
‘613-121-00-4 chlorsulfuron (ISO); 2-chloro-N-[[(4-methoxy-6-methyl-1,3,5-triazin-2- yl)amino]carbonyl]benzenesulphonamide 265-268-5 64902-72-3 Aquatic Acute 1Aquatic Chronic 1 H400H410 GHS09Wng H410  M = 1 000M = 100’ 
‘616-011-00-4 N,N-dimethylacetamide 204-826-4 127-19-5 Repr. 1BAcute Tox. 4*Acute Tox. 4* H360D***H332H312 GHS08GHS07Dgr H360D***H332H312’   
‘616-037-00-6 acetochlor (ISO); 2-chloro-N-(ethoxymethyl)-N-(2-ethyl-6-methylphenyl)acetamide 251-899-3 34256-82-1 Carc. 2Repr. 2Acute Tox. 4STOT SE 3STOT RE 2Skin Irrit. 2Skin Sens. 1Aquatic Acute 1Aquatic Chronic 1 H351H361fH332H335H373 (kidney)H315H317H400H410 GHS08GHS07GHS09Wng H351H361fH332H335H373 (kidney)H315H317H410  M = 1 000M = 100’ 
‘616-207-00-X polyhexamethylene biguanide hydrochloride;PHMB — 32289-58-027083-27-8 Carc. 2Acute Tox. 2Acute Tox. 4STOT RE 1Eye Dam. 1Skin Sens. 1BAquatic Acute 1Aquatic Chronic 1 H351H330H302H372 (respiratory tract) (inhalation)H318H317H400H410 GHS08GHS06GHS05GHS09Dgr H351H330H302H372 (respiratory tract) (inhalation)H318H317H410  M = 10M = 10’ 
((c)) the following entries are inserted in accordance with the order of the index numbers:

Index No International Chemical Identification EC No CAS No Classification Labelling Specific Conc. Limits, M-factors Notes
Hazard Class and Category Code(s) Hazard statement Code(s) Pictogram, Signal Word Code(s) Hazard statement Code(s) Suppl. Hazard statement Code(s)
‘005-020-00-3 disodium octaborate anhydrous; [1]disodium octaborate tetrahydrate [2] 234-541-0 [1]234-541-0 [2] 12008-41-2 [1]12280-03-4 [2] Repr. 1B H360FD GHS08Dgr H360FD’   
‘014-046-00-4 e-glass microfibres of representative composition; [Calcium-aluminium-silicate fibres with random orientation with the following representative composition (% given by weight): SiO2 50,0-56,0 %, Al2O3 13,0-16,0 %, B2O3 5,8-10,0 %, Na2O < 0,6 %, K2O < 0,4 %, CaO 15,0-24,0 %, MgO < 5,5 %, Fe2O3 < 0,5 %, F2 < 1,0 %. Process: typically produced by flame attenuation and rotary process. (Additional individual elements may be present at low levels; the process list does not preclude innovation).] — — Carc. 1B H350i GHS08Dgr H350i   A’
‘014-047-00-X glass microfibres of representative composition; [Calcium-aluminium-silicate fibres with random orientation with the following composition (% given by weight): SiO2 55,0-60,0 %, Al2O3 4,0-7,0 %, B2O3 8,0-11,0 %, ZrO2 0,0-4,0 %, Na2O 9,5-13,5 %, K2O 0,0-4,0 %, CaO 1,0-5,0 %, MgO 0,0-2,0 %, Fe2O3 < 0,2 %, ZnO 2,0-5,0 %, BaO 3,0-6,0 %, F2 < 1,0 %. Process: typically produced by flame attenuation and rotary process. (Additional individual elements may be present at low levels; the process list does not preclude innovation).] — — Carc. 2 H351 (inhalation) GHS08Wng H351 (inhalation)   A’
‘029-015-00-0 copper thiocyanate 214-183-1 1111-67-7 Aquatic Acute 1 Aquatic Chronic 1 H400H410 GHS09Wng H410 EUH032 M = 10’ 
‘029-016-00-6 copper(II) oxide 215-269-1 1317-38-0 Aquatic Acute 1Aquatic Chronic 1 H400H410 GHS09Wng H410  M = 100’ 
‘029-017-00-1 dicopper chloride trihydroxide 215-572-9 1332-65-6 Acute Tox. 4Acute Tox. 3Aquatic Acute 1Aquatic Chronic 1 H332H301H400H410 GHS06GHS09Dgr H332H301H410  M = 10’ 
‘029-018-00-7 tetracopper hexahydroxide sulphate; [1]tetracopper hexahydroxide sulphate hydrate [2] 215-582-3 [1]215-582-3 [2] 1333-22-8 [1]12527-76-3 [2] Acute Tox. 4Aquatic Acute 1 Aquatic Chronic 1 H302H400H410 GHS07GHS09Wng H302H410  M = 10’ 
‘029-019-01-X copper flakes (coated with aliphatic acid) — — Acute Tox. 3Acute Tox. 4Eye Irrit. 2Aquatic Acute 1Aquatic Chronic 1 H331H302H319H400H410 GHS06GHS09Dgr H331H302H319H410  M = 10’ 
‘029-020-00-8 copper(II) carbonate--copper(II) hydroxide (1:1) 235-113-6 12069-69-1 Acute Tox. 4Acute Tox. 4Eye Irrit. 2Aquatic Acute 1Aquatic Chronic 1 H332H302H319H400H410 GHS07GHS09Wng H332H302H319H410  M = 10’ 
‘029-021-00-3 copper dihydroxide;copper(II) hydroxide 243-815-9 20427-59-2 Acute Tox. 2Acute Tox. 4Eye Dam. 1Aquatic Acute 1Aquatic Chronic 1 H330H302H318H400H410 GHS06GHS05GHS09Dgr H330H302H318H410  M = 10’ 
‘029-022-00-9 bordeaux mixture;reaction products of copper sulphate with calcium dihydroxide — 8011-63-0 Acute Tox. 4Eye Dam. 1Aquatic Acute 1Aquatic Chronic 1 H332H318H400H410 GHS07GHS05GHS09Dgr H332H318H410  M = 10’ 
‘029-023-00-4 copper sulphate pentahydrate 231-847-6 7758-99-8 Acute Tox. 4Eye Dam. 1Aquatic Acute 1Aquatic Chronic 1 H302H318H400H410 GHS07GHS05GHS09Dgr H302H318H410  M = 10’ 
‘082-013-00-1 lead powder;[particle diameter < 1 mm] 231-100-4 7439-92-1 Repr. 1ALact. H360FDH362 GHS08Dgr H360FDH362  Repr. 1A; H360D: C ≥ 0,03 %’ 
‘082-014-00-7 lead massive:[particle diameter ≥ 1 mm] 231-100-4 7439-92-1 Repr. 1ALact. H360FDH362 GHS08Dgr H360FDH362’   
‘605-040-00-8 hydroxyisohexyl 3-cyclohexene carboxaldehyde (INCI); reaction mass of 4-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde and 3-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde; [1]4-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde; [2]3-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde [3] - [1]250-863-4 [2]257-187-9 [3] 130066-44-3 [1]31906-04-4 [2]51414-25-6 [3] Skin Sens. 1A H317 GHS07Wng H317’   
‘607-716-00-8 bromadiolone (ISO); 3-[3-(4′-bromobiphenyl-4-yl)-3-hydroxy-1-phenylpropyl]-4-hydroxy-2H-chromen-2-one 249-205-9 28772-56-7 Repr. 1BAcute Tox. 1Acute Tox. 1Acute Tox. 1STOT RE 1Aquatic Acute 1Aquatic Chronic 1 H360DH330H310H300H372 (blood)H400H410 GHS08GHS06GHS09Dgr H360DH330H310H300H372 (blood)H410  Repr. 1B; H360D:C ≥ 0,003 %STOT RE 1; H372 (blood): C ≥ 0,005 % STOT RE 2; H373 (blood):0,0005 % ≤ C < 0,005 %M = 1M = 1’ 
‘607-717-00-3 difethialone (ISO);3-[3-(4′-bromobiphenyl-4-yl)-1,2,3,4-tetrahydronaphthalen-1-yl]-4-hydroxy-2H-1-benzothiopyran-2-one — 104653-34-1 Repr. 1BAcute Tox. 1Acute Tox. 1Acute Tox. 1STOT RE 1Aquatic Acute 1Aquatic Chronic 1 H360DH330H310H300H372 (blood)H400H410 GHS08GHS06GHS09Dgr H360DH330H310H300H372 (blood)H410 EUH070 Repr. 1B; H360D:C ≥ 0,003 %STOT RE 1; H372 (blood): C ≥ 0,02 % STOT RE 2; H373 (blood):0,002 % ≤ C < 0,02 %M = 100M = 100’ 
‘607-718-00-9 perfluorononan-1-oic acid [1] and its sodium [2] and ammonium [3] salts 206-801-3 [1][2][3] 375-95-1 [1]21049-39-8 [2]4149-60-4 [3] Carc. 2Repr. 1BLact.Acute Tox. 4Acute Tox. 4STOT RE 1Eye Dam. 1 H351H360DfH362H332H302H372 (liver, thymus, spleen)H318 GSH08GSH07GHS05Dgr H351H360DfH362H332H302H372 (liver, thymus, spleen)H318’   
‘607-719-00-4 dicyclohexyl phthalate 201-545-9 84-61-7 Repr. 1BSkin Sens. 1 H360DH317 GHS08GHS07Dgr H360DH317’   
‘608-067-00-3 3,7-dimethylocta-2,6-dienenitrile 225-918-0 5146-66-7 Muta. 1B H340 GHS08Dgr H340’   
‘612-288-00-0 bupirimate (ISO);5-butyl-2-ethylamino-6-methylpyrimidin-4-yl dimethylsulphamate 255-391-2 41483-43-6 Carc. 2Skin Sens. 1BAquatic Chronic 1 H351H317H410 GHS08GHS07GHS09Wng H351H317H410  M = 1’ 
‘612-289-00-6 triflumizole (ISO);(1E)-N-[4-chloro-2-(trifluoromethyl)phenyl]-1-(1H-imidazol-1-yl)-2-propoxyethanimine — 68694-11-1 Repr. 1BAcute Tox. 4STOT RE 2Skin Sens. 1Aquatic Acute 1Aquatic Chronic 1 H360DH302H373 (liver)H317H400H410 GHS08GHS07GHS09Dgr H360DH302H373 (liver)H317H410  M = 1M = 1’ 
‘616-218-00-X benzovindiflupyr (ISO); N-[9-(dichloromethylene)-1,2,3,4-tetrahydro-1,4-methanonaphthalen-5-yl]-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide — 1072957-71-1 Acute Tox. 3Acute Tox. 3Aquatic Acute 1Aquatic Chronic 1 H331H301H400H410 GHS06GHS09Dgr H331H301H410  M = 100M = 100’ 
‘616-219-00-5 fluopyram (ISO); N-{2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]ethyl}-2-(trifluoromethyl)benzamide — 658066-35-4 Aquatic Chronic 2 H411 GHS09 H411’   
‘616-220-00-0 pencycuron (ISO); 1-[(4-chlorophenyl)methyl]-1-cyclopentyl-3-phenylurea 266-096-3 66063-05-6 Aquatic Acute 1Aquatic Chronic 1 H400H410 GHS09Wng H410  M = 1M = 1’ 
‘617-023-00-2 tert-butyl hydroperoxide 200-915-7 75-91-2 Muta. 2 H341 GHS08Wng H341’   
